Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3858-3867

  Wen, Yugang ^a   Wang, Quan ^a   Zhou, Chongzhi ^a   Yan, Dongwang ^a   Qiu, Guoqiang ^a   Yang, Chun ^b   Tang, Huamei ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN RASSF6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; STOMACH CANCER; TISSUE MICROARRAY; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GASTRIC MUCOSA; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955167920     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1668-5     Document Type: Article

References (35)

1. WK Leung MS Wu Y Kakugawa, et al. 2008 Screening for gastric cancer in Asia: current evidence and practice Lancet Oncol. 9 279 287 18308253 10.1016/S1470-2045(08)70072-X (Pubitemid 351722947)
2. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics CA Cancer J Clin. 60 277 300 20610543 10.3322/caac.20073
3. D Cunningham J Oliveira 2008 Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann Oncol 19 ii23 ii24 18456755 10.1093/annonc/mdn075
4. MF de Maat CJ van de Velde N Umetani, et al. 2007 Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer J Clin Oncol 25 31 4887 4894 17971584 10.1200/JCO.2006.09.8921 (Pubitemid 350220418)
5. JS MacDonald 2006 Gastric cancer: new therapeutic options N Engl J Med. 355 76 77 16822999 10.1056/NEJMe068121 1:CAS:528:DC%2BD28Xms1Gkt78%3D (Pubitemid 43053709)
6. SA Hundahl HJ Wanebo 2005 Changing gastric cancer treatment in the United States and the pursuit of quality Eur J Surg Oncol. 31 605 615 16023944 10.1016/j.ejso.2005.02.011 1:STN:280:DC%2BD2Mzms1emug%3D%3D (Pubitemid 40975242)
7. C Gravalos A Jimeno 2008 HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol. 19 1523 1529 18441328 10.1093/annonc/mdn169 1:STN:280:DC%2BD1crivFajtQ%3D%3D
8. HH Ishii GC Gobe Y Ebihara 2007 P53 is an indicator of tumor progression in early but not advanced gastric carcinomas Hepatogastroenterology 54 79 2159 2163 18251181
9. M Scartozzi E Galizia F Freddari R Berardi R Cellerino S Cascinu 2004 Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches Cancer Treat Rev 30 5 451 459 15245777 10.1016/j.ctrv.2004.01.001 1:CAS:528:DC%2BD2cXlsFyiu7g%3D (Pubitemid 38968125)
10. JH Kim MK Kim HE Lee, et al. 2007 Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer Mod Pathol. 20 835 842 17491598 10.1038/modpathol.3800789 1:CAS:528: DC%2BD2sXnvVeks70%3D (Pubitemid 47077265)
11. E Lieto F Ferraraccio M Orditura, et al. 2008 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients Ann Surg Oncol 15 1 69 79 17896140 10.1245/s10434-007-9596-0
12. Q Wang YG Wen DP Li, et al. 2010 Refined mapping of loss of heterozygosity in Chinese sporadic gastric carcinoma Afr J Biotechnol 9 35 5754 5761 1:CAS:528:DC%2BC3cXhtFSqs7jF
13. YG Wen Q Wang CZ Zhou GQ Qiu ZH Peng HM Tang 2010 Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3 K/AKT pathway Oncol Rep. 24 89 95 20514448 1:CAS:528:DC%2BC3cXpt1ahtL8%3D
14. K Eckfeld L Hesson MD Vos I Bieche F Latif GJ Clark 2004 RASSF4/AD037 is a potential Ras effector/tumor suppressor of the RASSF family Cancer Res. 64 8688 8693 15574778 10.1158/0008-5472.CAN-04-2065 1:CAS:528:DC%2BD2cXhtVCjs7rI (Pubitemid 39552084)
15. LVD Weyden DJ Adams 2007 The Ras-association domain family (RASSF) members and their role in human tumourigenesis Biochim Biophys Acta. 1776 58 85 17692468 (Pubitemid 47332074)
16. AM Richter GP Pfeifer RH Dammann 2009 The RASSF proteins in cancer; from epigenetic silencing to functional characterization Biochim Biophys Acta. 1796 114 128 19344752 1:CAS:528:DC%2BD1MXhtFyqsLjL
17. NPC Allen H Donninger MD Vos, et al. 2007 RASSF6 is a novel member of the RASSF family of tumor suppressors Oncogene. 26 6203 6211 17404571 10.1038/sj.onc.1210440 1:CAS:528:DC%2BD2sXhtVeisLvE (Pubitemid 47414375)
18. M Ikeda S Hirabayashi N Fujiwara, et al. 2007 Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways Exp Cell Res. 313 1484 1495 17367779 10.1016/j.yexcr.2007.02.013 1:CAS:528:DC%2BD2sXjvFGrsb0%3D (Pubitemid 46507453)
19. T Scholzen J Gerdes 2000 The Ki-67 protein: from the known and the unknown J Cell Physiol. 182 311 322 10653597 10.1002/(SICI)1097-4652(200003)182: 3<311::AID-JCP1>3.0.CO;2-9 1:CAS:528:DC%2BD3cXot1Ggsg%3D%3D (Pubitemid 30054364)
20. AC Tsamandas D Kardamakis P Tsiamalos, et al. 2009 The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome Anticancer Res 29 2 703 709 19331225
21. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss; 2002.
22. J Ajani TA D'Amico JA Hayman NJ Meropol B Minsky 2003 National Comprehensive Cancer Network. Gastric cancer: Clinical practice guidelines in oncology J Natl Compr Canc Netw 1 1 28 39 19764148
23. IM Bachmann HE Puntervoll AP Otte LA Akslen 2008 Loss of BMI-1 expression is associated with clinical progress of malignant melanoma Mod Pathol. 21 583 590 18246051 10.1038/modpathol.2008.17 1:CAS:528:DC%2BD1cXltVGksrk%3D (Pubitemid 351589652)
24. XP Liu K Tsushimi M Tsushimi S Kawauchi A Oga T Furuya K Sasaki 2001 Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: Its relationships with cell proliferation activity and prognosis Cancer Lett. 170 183 189 11463497 10.1016/S0304-3835(01)00589-4 1:CAS:528:DC%2BD3MXltFyqtL4%3D (Pubitemid 32709919)
25. DW Yan DW Li YX Yang, et al. 2010 Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery Br J Cancer 103 7 961 969 20808312 10.1038/sj.bjc.6605870 1:CAS:528:DC%2BC3cXht1WlsrbK
26. A Agathanggelou WN Cooper F Latif 2005 Role of the Ras-association domain family 1 tumor suppressor gene in human cancers Cancer Res. 65 3497 3508 15867337 10.1158/0008-5472.CAN-04-4088 1:CAS:528:DC%2BD2MXjslGltLc%3D (Pubitemid 40616319)
27. G Cattoretti MH Becker G Key M Duchrow C Schlüter J Galle J Gerdes 1992 Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MI B 1 and MI B 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections J Pathol. 168 357 363 1484317 10.1002/path.1711680404 1:CAS:528:DyaK3sXhsVartLc%3D (Pubitemid 23013251)
28. C Niimi H Goto N Ohmiya Y Niwa T Hayakawa T Nagasaka N Nakashima 2002 Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma Am J Clin Pathol. 118 683 692 12428787 10.1309/NYA1-V9KQ-NVF8-MA8M (Pubitemid 37046312)
29. W Yasui N Oue PP Aung S Matsumura M Shutoh H Nakayama 2005 Molecular-pathological prognostic factors of gastric cancer: a review Gastric Cancer. 8 86 94 15864715 10.1007/s10120-005-0320-0 1:CAS:528: DC%2BD2MXjvVCntbY%3D (Pubitemid 40655517)
30. E Briasoulis T Liakakos L Dova M Fatouros P Tsekeris DH Roukos AM Kappas 2006 Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer Expert Rev Anticancer Ther. 6 931 939 16761937 10.1586/14737140.6.6.931 (Pubitemid 44201562)
31. S Jüttner C Wissmann T Jöns, et al. 2006 Vascular endothelial growth factor-D and its receptor VEGF-3: two novel independent prognostic markers in gastric adenocarcinoma J Clin Oncol. 24 228 240 16344322 10.1200/JCO.2004.00.3467 (Pubitemid 46622052)
32. KH Huang JH Chen CW Wu SS Lo MC Hsieh AF Li WY Lui 2009 Factors affecting recurrence in node-negative advanced gastric cancer J Gastroenterol Hepatol. 24 1522 1526 19467143 10.1111/j.1440-1746.2009.05844.x
33. S Baksh S Tommasi S Fenton, et al. 2005 The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death Mol Cell. 18 637 650 15949439 10.1016/j.molcel.2005.05.010 1:CAS:528: DC%2BD2MXlslCjtbo%3D (Pubitemid 40804800)
34. MD Vos A Dallol K Eckfeld, et al. 2006 The RASSF1A tumor suppressor activates Bax via MOAP-1 J Biol Chem. 281 4557 4563 16344548 10.1074/jbc.M512128200 1:CAS:528:DC%2BD28Xhs1elu78%3D (Pubitemid 43847713)
35. J Hull K Rowlands E Lockhart M Sharland C Moore N Hanchard DP Kwiatkowski 2004 Haplotype mapping of the bronchiolitis susceptibility locus near IL8 Hum Genet. 114 272 279 14605870 10.1007/s00439-003-1038-x 1:CAS:528: DC%2BD2cXmtlGgtg%3D%3D (Pubitemid 38208305)